The original NINDS-SPSP criteria generally led to a diagnosis 3 to 4 years after onset, based on the appearance of primary symptoms such as supranuclear gaze palsy and frequent falls corresponding to the core domains of ocular motor dysfunction and postural instability. The MDS guidelines added the 2 domains of akinesia and cognitive function and increased the sensitivity of the criteria to allow for diagnosis much sooner in the disease course. “The new diagnostic criteria aim to optimize an early recognition of PSP patients, before massive functional deficits are established, capturing the entire clinical spectrum of the disease,” Dr Höglinger said.

He pointed to a number of symptomatic treatments for PSP that are “moderately effective,” such as levodopa and amantadine for akinesia, amitriptyline and zolpidem for ocular motor symptoms, zolpidem for sleep disturbances, coenzyme Q10 to improve motor and neuropsychological symptoms, and botulinum toxin A for focal dystonia.31 More important, he noted, the new criteria allow for the initiation of treatment in the earliest clinical phase with novel disease-modifying therapies now in development, such as tau antibodies, and can be used in the design of future clinical trials.


Continue Reading

Despite the added complexity of the new guidelines, Dr Höglinger suggested that application in clinical settings should only take about 15 minutes for an experienced neurologist, particularly when using a schematic grid such as the one provided in the guidelines article published in Movement Disorders.1

“The major novelty is just the awareness that combinations of clinical features can be associated with a neuropathological diagnosis of PSP, which we did not have on the radar previously,” he explained. The investigative group is already at work on a web-based tool that will enable widespread implementation of the guidelines, which they expect to have available within a year.

References

  1. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria [published online May 3, 2017]. Mov Disord. doi: 10.1002/mds.26987
  2. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewkski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996:47:1-9.
  3. Litvan I, Campbell G, Mangone CA, et al. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewkski syndrome) from related disorders? A clinicopathological study. Brain. 1997;120:67-74.
  4. Lopez OL, Litvan I, Catt K, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of four neurodegenerative dementias. Neurology. 1999:53:1292-1299.
  5. Osaki Y, Ben-Shlomo Y, Lees AJ, et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord. 2004;19:181-189.
  6. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain. 2005;128:1247-1258.
  7. Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014;14:1758-1766.
  8. Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord. 2002;17:1255-1264.
  9. Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord. 2010;25:357-362.
  10. Litvan I, Mangone CA, McKee A, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. 1998;64:184-189.
  11. Donker Kaat L, Boon AJ, Kamphorst W, et al. Frontal presentation in progressive supranuclear palsy. Neurology. 2007;69:723-729.
  12. Han HJ, Kim H, Park JH, et al. Behavioral changes as the earliest clinical manifestation of progressive supranuclear palsy. Clin Neurol. 2010;6:148-151.
  13. Hassan A, Parisi E, Josephs KA. Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia. Neurocase. 2012;18:478-488.
  14. Compta Y, Alldeoriola F, Tolosa E, et al. Long lasting pure freezing of gait preceding progressive supranuclear palsy: a clinicopathological study. Mov Disord. 2007;22:1954-1958.
  15. Facheris MF, Maniak S, Scaravilli F, et al. Pure akinesia as initial presentation of PSP: a clinicopathological study. Parkinsonism Relat Disord. 2008;14:517-519.
  16. Williams DR, Holton JL, Strand K, Revesv T, Lees, AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord. 2007;22:2235-2241.
  17. Tsuboi Y, Josephs KA, Boeve BF, et al. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord. 2005;20:982-928.
  18. Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006;66:41-48.
  19. Ling H, de Silva R, Massey LA, et al. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant. Neuropathol Appl Neurobiol. 2014;40:149-163.
  20. Ling H, O’Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010;133:2045-2057.
  21. Josephs KA, Katsuse O, Beccano-Kelly DA, et al. Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol. 2006;65:396-405.
  22. Nagao S, Yokota O, Nanba R, et al. Progressive supranuclear palsy presenting as primary lateral sclerosis but lacking parkinsonism, gaze palsy, aphasia, or dementia. J Neurol Sci. 2012;323:147-153.
  23. Kanazawa M, Shimohata T, Toyoshima Y, et al. Cerebellar involvement in progressive supranuclear palsy: a clinicopathological study. Mov Disord. 2009;24:1312-1318.
  24. Iwasaki Y, Mori K, Ito M, et al. An autopsied case of progressive supranuclear palsy presenting with cerebellar ataxia and severe cerebellar involvement. Neuropathology. 2013;33:561-567.
  25. Kanazawa M, Tada M, Onodera O, et al. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia. Parkinsonism Relat Disord. 2013;19:1149-1151.
  26. Koga S, Josephs KA, Ogaki K, et al. Cerebellar ataxia in progressive supranuclear palsy: an autopsy study of PSP-C. Mov Disord. 2016;31:653-662.
  27. Boeve B, Dickson D, Duffy J, et al. Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. Eur Neurol. 2003;49:72-78.
  28. Mochizuki A, Ueda Y, Komatsuzaki Y, et al. Progressive supranuclear palsy presenting with primary progressive aphasia–clinicopathological report of an autopsy case. Acta Neuropathol. 2003;105:610-614.
  29. Josephs KA, Duffy JR, Strand EA, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain. 2006;129:1385-1398.
  30. Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol. 2008;21:688-692.
  31. Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU. The differential diagnosis and treatment of atypical parkinsonism. Dtsch Arztebl Int. 2016;113:61-69.